Vaccines in the treatment of invasive candidiasis

References

• Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH. An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 2010; 9:719-27; PMID:20725094; http://dx.doi.org/10.1038/nrd3074
   PubMed Web of Science ®Google Scholar
• Liao Y, Chen M, Hartmann T, Yang RY, Liao WQ. Epidemiology of opportunistic invasive fungal infections in China: review of literature. Chin Med J (Engl) 2013; 126:361-8; PMID:23324290
   PubMed Web of Science ®Google Scholar
• Romani L. Immunity to fungal infections. Nat Rev Immunol 2004; 4:1-23; PMID:14661066
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Viasus D, Carratala J. Pathogenesis of invasive fungal infections. Curr Opin Infect Dis 2013; 26:270-6; PMID:23449139; http://dx.doi.org/10.1097/QCO.0b013e32835fb920
   PubMed Web of Science ®Google Scholar
• Dan JM, Levitz SM. Prospects for development of vaccines against fungal diseases. Drug Resist Updat 2006; 9:105-10; PMID:16820318; http://dx.doi.org/10.1016/j.drup.2006.05.004
   PubMed Web of Science ®Google Scholar
• Cassone A. Fungal vaccines: real progress from real challenges. Lancet Infect Dis 2008; 8:114-24; PMID:18222162; http://dx.doi.org/10.1016/S1473-3099(08)70016-1
   PubMed Web of Science ®Google Scholar
• Spellberg B. Vaccines for invasive fungal infections. F1000 Med Rep 2011; 3:13; PMID:21876719; http://dx.doi.org/10.3410/M3-13
   PubMedGoogle Scholar
• Cutler JE, Deepe GS, Jr., Klein BS. Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol 2007; 5:13-28; PMID:17160002; http://dx.doi.org/10.1038/nrmicro1537
   PubMed Web of Science ®Google Scholar
• Casadevall A. Antibody immunity and invasive fungal infections. Infect Immun 1995; 63:4211-8; PMID:7591049
   PubMed Web of Science ®Google Scholar
• Spellberg BJ, Ibrahim AS, Avenissian V, Filler SG, Myers CL, Fu Y, Edwards JE, Jr. The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect Immun 2005; 73:6191-3; PMID:16113347; http://dx.doi.org/10.1128/IAI.73.9.6191-6193.2005
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Spellberg BJ, Avanesian V, Fu Y, Edwards JE, Jr. The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis. Infect Immun 2006; 74:3039-41; PMID:16622247; http://dx.doi.org/10.1128/IAI.74.5.3039-3041.2006
   PubMed Web of Science ®Google Scholar
• Spellberg BJ, Ibrahim AS, Avanesian V, Fu Y, Myers C, Phan QT, Filler SG, Yeaman MR, Edwards JE, Jr. Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis 2006; 194:256-60; PMID:16779733; http://dx.doi.org/10.1086/504691
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Luo G, Gebremariam T, Lee H, Schmidt CS, Hennessey JP, Jr, French SW, Yeaman MR, Filler SG, Edwards JE, Jr. NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response. Vaccine 2013; 31:5549-56; PMID:24063977; http://dx.doi.org/10.1016/j.vaccine.2013.09.016
   PubMed Web of Science ®Google Scholar
• Edwards JE, Jr. Fungal cell wall vaccines: an update. J Med Microbiol 2012; 61:895-903; PMID:22267544; http://dx.doi.org/10.1099/jmm.0.041665-0
   PubMed Web of Science ®Google Scholar
• Schmidt CS, White CJ, Ibrahim AS, Filler SG, Fu Y, Yeaman MR, Edwards JE, Jr, Hennessey JP, Jr. NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine 2012; 30:7594-600; PMID:23099329; http://dx.doi.org/10.1016/j.vaccine.2012.10.038
   PubMed Web of Science ®Google Scholar
• Saville SP, Lazzell AL, Chaturvedi AK, Monteagudo C, Lopez-Ribot JL. Use of a genetically engineered strain to evaluate the pathogenic potential of yeast cell and filamentous forms during Candida albicans systemic infection in immunodeficient mice. Infect Immun 2008; 76:97-102; PMID:17967861; http://dx.doi.org/10.1128/IAI.00982-07
   PubMed Web of Science ®Google Scholar
• Saville SP, Lazzell AL, Chaturvedi AK, Monteagudo C, Lopez-Ribot JL. Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis. Clin Vaccine Immunol 2009; 16:430-2; PMID:19144791; http://dx.doi.org/10.1128/CVI.00480-08
   PubMed Web of Science ®Google Scholar
• Cassone A. Development of vaccines for Candida albicans: fighting a skilled transformer. Nat Rev Microbiol 2013; 11:884-91; PMID:24232568; http://dx.doi.org/10.1038/nrmicro3156
   PubMed Web of Science ®Google Scholar
• Cassone A, Casadevall A. Recent progress in vaccines against fungal diseases. Curr Opin Microbiol 2012; 15:427-33; PMID:22564747; http://dx.doi.org/10.1016/j.mib.2012.04.004
   PubMed Web of Science ®Google Scholar
• Gropp K, Schild L, Schindler S, Hube B, Zipfel PF, Skerka C. The yeast Candida albicans evades human complement attack by secretion of aspartic proteases. Mol Immunol 2009; 47:465-75; PMID:19880183; http://dx.doi.org/10.1016/j.molimm.2009.08.019
   PubMed Web of Science ®Google Scholar
• Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 2003; 67:400-28; table of contents; PMID:12966142; http://dx.doi.org/10.1128/MMBR.67.3.400-428.2003
   PubMed Web of Science ®Google Scholar
• Naglik J, Albrecht A, Bader O, Hube B. Candida albicans proteinases and host/pathogen interactions. Cell Microbiol 2004; 6:915-26; PMID:15339267; http://dx.doi.org/10.1111/j.1462-5822.2004.00439.x
   PubMed Web of Science ®Google Scholar
• Lian CH, Liu WD. Differential expression of Candida albicans secreted aspartyl proteinase in human vulvovaginal candidiasis. Mycoses 2007; 50:383-90; PMID:17714358; http://dx.doi.org/10.1111/j.1439-0507.2007.01384.x
   PubMed Web of Science ®Google Scholar
• De Bernardis F. Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis. Infecti Immun 2002; 70:2725-9; PMID:11953420; http://dx.doi.org/10.1128/IAI.70.5.2725-2729.2002
   PubMed Web of Science ®Google Scholar
• De Bernardis F, Amacker M, Arancia S, Sandini S, Gremion C, Zurbriggen R, Moser C, Cassone A. A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models. Vaccine 2012; 30:4490-8; PMID:22561143; http://dx.doi.org/10.1016/j.vaccine.2012.04.069
   PubMed Web of Science ®Google Scholar
• Fu Y, Ibrahim AS, Sheppard DC, Chen YC, French SW, Cutler JE, Filler SG, Edwards JE, Jr. Candida albicans Als1p: an adhesin that is a downstream effector of the EFG1 filamentation pathway. Mol Microbiol 2002; 44:61-72; PMID:11967069; http://dx.doi.org/10.1046/j.1365-2958.2002.02873.x
   PubMed Web of Science ®Google Scholar
• Fu Y, Rieg G, Fonzi WA, Belanger PH, Edwards JE, Jr., Filler SG. Expression of the Candida albicans gene ALS1 in Saccharomyces cerevisiae induces adherence to endothelial and epithelial cells. Infect Immun 1998; 66:1783-6; PMID:9529114
   PubMed Web of Science ®Google Scholar
• Loza L, Fu Y, Ibrahim AS, Sheppard DC, Filler SG, Edwards JE, Jr. Functional analysis of the Candida albicans ALS1 gene product. Yeast 2004; 21:473-82; PMID:15116430; http://dx.doi.org/10.1002/yea.1111
   PubMed Web of Science ®Google Scholar
• Sheppard DC, Yeaman MR, Welch WH, Phan QT, Fu Y, Ibrahim AS, Filler SG, Zhang M, Waring AJ, Edwards JE, Jr. Functional and structural diversity in the Als protein family of Candida albicans. J Biol Chem 2004; 279:30480-9; PMID:15128742; http://dx.doi.org/10.1074/jbc.M401929200
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Spellberg BJ, Avenissian V, Fu Y, Filler SG, Edwards JE, Jr. Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect Immun 2005; 73:999-1005; PMID:15664943; http://dx.doi.org/10.1128/IAI.73.2.999-1005.2005
   PubMed Web of Science ®Google Scholar
• Spellberg B, Ibrahim AS, Lin L, Avanesian V, Fu Y, Lipke P, Otoo H, Ho T, Edwards JE, Jr. Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity. J Infect Dis 2008; 197:967-71; PMID:18419471; http://dx.doi.org/10.1086/529204
   PubMed Web of Science ®Google Scholar
• Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, Fu Y, French SW, Edwards JE, Jr., Spellberg B. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009; 5:e1000703; PMID:20041174; http://dx.doi.org/10.1371/journal.ppat.1000703
   PubMed Web of Science ®Google Scholar
• Zhao X, Oh SH, Cheng G, Green CB, Nuessen JA, Yeater K, Leng RP, Brown AJ, Hoyer LL. ALS3 and ALS8 represent a single locus that encodes a Candida albicans adhesin; functional comparisons between Als3p and Als1p. Microbiology 2004; 150:2415-28; PMID:15256583; http://dx.doi.org/10.1099/mic.0.26943-0
   PubMed Web of Science ®Google Scholar
• Phan QT, Myers CL, Fu Y, Sheppard DC, Yeaman MR, Welch WH, Ibrahim AS, Edwards JE, Jr., Filler SG. Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol 2007; 5:e64; PMID:17311474
   PubMed Web of Science ®Google Scholar
• Raska M, Belakova J, Horynova M, Krupka M, Novotny J, Sebestova M, Weigl E. Systemic and mucosal immunization with Candida albicans hsp90 elicits hsp90-specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis. Med Mycol 2008; 46:411-20; PMID:18608941; http://dx.doi.org/10.1080/13693780701883508
   PubMed Web of Science ®Google Scholar
• Matthews RC, Burnie JP. Recombinant antibodies: a natural partner in combinatorial antifungal therapy. Vaccine 2004; 22:865-71; PMID:15040939; http://dx.doi.org/10.1016/j.vaccine.2003.11.032
   PubMed Web of Science ®Google Scholar
• Raska M, Belakova J, Wudattu NK, Kafkova L, Ruzickova K, Sebestova M, Kolar Z, Weigl E. Comparison of protective effect of protein and DNA vaccines hsp90 in murine model of systemic candidiasis. Folia Microbiol (Praha) 2005; 50:77-82; PMID:15954537
   PubMed Web of Science ®Google Scholar
• Bugli F, Cacaci M, Martini C, Torelli R, Posteraro B, Sanguinetti M, Paroni Sterbini F. Human monoclonal antibody-based therapy in the treatment of invasive candidiasis. Clin Dev Immunol 2013; 2013:403121; PMID:23878583; http://dx.doi.org/10.1155/2013/403121
   PubMedGoogle Scholar
• Matthews RC, Rigg G, Hodgetts S, Carter T, Chapman C, Gregory C, Illidge C, Burnie J. Preclinical Assessment of the Efficacy of Mycograb, a Human Recombinant Antibody against Fungal HSP90. Antimicrob Agents Chemother 2003; 47:2208-16; PMID:12821470; http://dx.doi.org/10.1128/AAC.47.7.2208-2216.2003
   PubMed Web of Science ®Google Scholar
• Cassone A, Bromuro C, Chiani P, Torosantucci A. Hyr1 protein and beta-glucan conjugates as anti-Candida vaccines. J Infect Dis 2010; 202:1930; PMID:21083372; http://dx.doi.org/10.1086/657417
   PubMed Web of Science ®Google Scholar
• Bailey DA, Feldmann PJ, Bovey M, Gow NA, Brown AJ. The Candida albicans HYR1 gene, which is activated in response to hyphal development, belongs to a gene family encoding yeast cell wall proteins. J Bacteriol 1996; 178:5353-60; PMID:8808922
   PubMed Web of Science ®Google Scholar
• Luo G, Ibrahim AS, Spellberg B, Nobile CJ, Mitchell AP, Fu Y. Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target. J Infect Dis 2010; 201:1718-28; PMID:20415594; http://dx.doi.org/10.1086/652407
   PubMed Web of Science ®Google Scholar
• Thomas DP, Viudes A, Monteagudo C, Lazzell AL, Saville SP, Lopez-Ribot JL. A proteomic-based approach for the identification of Candida albicans protein components present in a subunit vaccine that protects against disseminated candidiasis. Proteomics 2006; 6:6033-41; PMID:17051645; http://dx.doi.org/10.1002/pmic.200600321
   PubMed Web of Science ®Google Scholar
• Johnson MA, Bundle DR. Designing a new antifungal glycoconjugate vaccine. Chem Soc Rev 2013; 42:4327-44; PMID:23232662; http://dx.doi.org/10.1039/c2cs35382b
   PubMed Web of Science ®Google Scholar
• Bystricky S, Paulovicova E, Machova E. Candida albicans mannan-protein conjugate as vaccine candidate. Immunol Lett 2003; 85:251-5; PMID:12663139; http://dx.doi.org/10.1016/S0165-2478(02)00241-9
   PubMed Web of Science ®Google Scholar
• Han Y, Rhew KY. Comparison of two Candida mannan vaccines: the role of complement in protection against disseminated candidiasis. Arch Pharm Res 2012; 35:2021-7; PMID:23212645; http://dx.doi.org/10.1007/s12272-012-1120-9
   PubMed Web of Science ®Google Scholar
• Luong M, Lam JS, Chen J, Levitz SM. Effects of fungal N- and O-linked mannosylation on the immunogenicity of model vaccines. Vaccine 2007; 25:4340-4; PMID:17412460; http://dx.doi.org/10.1016/j.vaccine.2007.03.027
   PubMed Web of Science ®Google Scholar
• Lipinski T, Fitieh A, St Pierre J, Ostergaard HL, Bundle DR, Touret N. Enhanced immunogenicity of a tricomponent mannan tetanus toxoid conjugate vaccine targeted to dendritic cells via Dectin-1 by incorporating beta-glucan. J Immunol 2013; 190:4116-28; PMID:23514738; http://dx.doi.org/10.4049/jimmunol.1202937
   PubMed Web of Science ®Google Scholar
• Xin H, Cartmell J, Bailey JJ, Dziadek S, Bundle DR, Cutler JE. Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis. PLoS One 2012; 7:e35106; PMID:2256337; http://dx.doi.org/10.1371/journal.pone.0035106
   PubMed Web of Science ®Google Scholar
• Lam JS, Mansour MK, Specht CA, Levitz SM. A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity. J Immunol 2005; 175:7496-503; PMID:16301657; http://dx.doi.org/10.4049/jimmunol.175.11.7496
   PubMed Web of Science ®Google Scholar
• Xin H, Dziadek S, Bundle DR, Cutler JE. Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis. Proc Natl Acad Sci U S A 2008; 105:13526-31; PMID:18725625; http://dx.doi.org/10.1073/pnas.0803195105
   PubMed Web of Science ®Google Scholar
• Xin H, Cutler JE. Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis. Clin Vaccine Immunol 2011; 18:1656-67; PMID:21832099; http://dx.doi.org/10.1128/CVI.05215-11
   PubMed Web of Science ®Google Scholar
• Pietrella D, Rachini A, Torosantucci A, Chiani P, Brown AJ, Bistoni F, Costantino P, Mosci P, d'Enfert C, Rappuoli R, et al. A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. Vaccine 2010; 28:1717-25; PMID:20038431; http://dx.doi.org/10.1016/j.vaccine.2009.12.021
   PubMed Web of Science ®Google Scholar
• Bromuro C, Romano M, Chiani P, Berti F, Tontini M, Proietti D, Mori E, Torosantucci A, Costantino P, Rappuoli R, et al. Beta-glucan-CRM197 conjugates as candidates antifungal vaccines. Vaccine 2010; 28:2615-23; PMID:20096763; http://dx.doi.org/10.1016/j.vaccine.2010.01.012
   PubMed Web of Science ®Google Scholar
• Specht CA, Nong S, Dan JM, Lee CK, Levitz SM. Contribution of glycosylation to T cell responses stimulated by recombinant Cryptococcus neoformans mannoprotein. J Infect Dis 2007; 196:796-800; PMID:17674324; http://dx.doi.org/10.1086/520536
   PubMed Web of Science ®Google Scholar
• Eggert AA, Schreurs MW, Boerman OC, Oyen WJ, de Boer AJ, Punt CJ, Figdor CG, Adema GJ. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999; 59:3340-5; PMID:10416590
   PubMed Web of Science ®Google Scholar
• Brena S, Omaetxebarria MJ, Elguezabal N, Cabezas J, Moragues MD, Ponton J. Fungicidal monoclonal antibody C7 binds to Candida albicans Als3. Infection and immunity 2007; 75:3680-2; PMID:17452471; http://dx.doi.org/10.1128/IAI.01840-06
   PubMed Web of Science ®Google Scholar
• Moragues MD, Omaetxebarria MJ, Elguezabal N, Sevilla MJ, Conti S, Polonelli L, Ponton J. A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities. Infection and immunity 2003; 71:5273-9; PMID:12933874; http://dx.doi.org/10.1128/IAI.71.9.5273-5279.2003
   PubMed Web of Science ®Google Scholar